AI-Powered Pathology Technology Company Develops Pan-Cancer Initiatives Across the Drug Development Lifecycle
PathAI and Aster Insights Partner to Deliver Combined AI-Derived Structured Pathology and Multimodal Real-World Data Solutions
AI-powered pathology technology company PathAI has partnered with Aster Insights. The new partnership will develop curated multimodal datasets that pair PathAI’s PathExplore artificial intelligence (AI) tumor microenvironment (TME) quantification panel with Aster Insights’ Avatar clinical, molecular, and digital pathology imaging data. By combining their respective best-in-class platforms, PathAI and Aster Insights will be able to expedite the development of novel insights to accelerate the discovery and development of new treatments for patients with cancer.
Top AI ML News: PolyAI Optmizes its Conversational AI to Automate Customer Services
PathAI and Aster Insights are offering these joint solutions to biopharma customers to support targeted and pan-cancer initiatives across the drug development lifecycle.
Ai-Powered Pathology Technology for Better Drug Development Outcomes
PathAI is the only AI-focused pathology technology company to provide comprehensive precision solutions from wet lab services to algorithm deployment for clinical trials to the industry leading AISight Image Management System. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge biomarker status and accelerate drug development for complex diseases.
The partnership will allow PathAI to utilize digital whole slide imaging (WSI) from Aster Insights’ Oncology Research Information Exchange Network® (ORIEN). ORIEN® members participate in Total Cancer Care® (TCC), the world’s largest and longest-running observational research study in oncology, which has accrued over 400,000 patients to date.
Digital pathology images contain a wealth of untapped data, and PathAI’s PathExplore is the world’s first structured, standardized, and scalable product that leverages AI to characterize the TME from routinely available hematoxylin and eosin (H&E) stained digital WSIs. PathExplore exhaustively detects and classifies the millions of cell and tissue regions across H&E WSIs to provide researchers access to important insights, such as patterns of immune cell infiltration and presence of complex tissue structures. These data are critical for better understanding existing treatments and the development of novel therapeutics.
Read AiThority.com News: How People Trick Generative Artificial Intelligence Chatbots into Exposing Company Secrets
PathExplore features are paired with Aster’s Avatar multimodal data including tumor whole exome and whole transcriptome sequencing, which allows researchers to follow a patient throughout their cancer journey and access rich information about their cancer biology. Avatar provides a powerful set of data, allowing for a deeper understanding of disease pathology, and what happens to patients when they are exposed to certain treatments.
“Analysis of histopathology images uniquely allows researchers to define and quantify spatial changes in the tumor microenvironment resulting from treatment or disease progression,” said Andy Beck, M.D., Ph.D., Chief Executive Officer and Co-founder of PathAI.
Dr. Andy added, “Our collaboration with Aster Insights is empowering researchers with robust multimodal datasets to explore hypotheses such as identifying and analyzing novel histological biomarkers correlated with patient treatment, outcomes, and gene expression.”
“Our approach to leveraging AI with multimodal data will lead to new information and deeper insights than currently possible,” said Anand Shah, M.D., Chief Executive Officer of Aster Insights. “Together with PathAI, we are creating new knowledge that is critical for researchers and life sciences partners to expand therapeutic options.
Recommended: 10 AI ML In Supply Chain Management Trends To Look Out For In 2024
Comments are closed.